(Q41717140)

7 October 2017

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? (English)

1 reference

7 October 2017

2

1 reference

7 October 2017

Burton DR

1

1 reference

PubMed ID

10655088

7 October 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

7 October 2017

1 reference

7 October 2017

6

1 reference

7 October 2017

123-125

1 reference

7 October 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/72200

7 October 2017

0 references

cites work

Six decades of vaccine development--a personal history

1 reference

7 January 2021

Antibody-mediated protection against intracellular pathogens

1 reference

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

7 January 2021

Biochemical analysis of the secreted and virion glycoproteins of Ebola virus

1 reference

7 January 2021

Ebola virus can be effectively neutralized by antibody produced in natural human infection

1 reference

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

7 January 2021

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

7 January 2021

Applications of DNA shuffling to pharmaceuticals and vaccines

1 reference

7 January 2021

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

1 reference

7 January 2021

The immunotargeting approach to adjuvant-independent subunit vaccine design

1 reference

7 January 2021

Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization

1 reference

7 January 2021

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants

1 reference

7 January 2021

Identifiers

DOI

10.1038/72200

1 reference

7 October 2017

1 reference

PubMed ID

10655088